Weekend update: The spinning of Baby Einstein, multiple-med confusion, and more
(UPDATED: See below.)
Revisiting a few life-science stories you might have missed over the weekend:
“Baby Einstein” creator’s defense: We were just kidding! — You have to feel at least a little sorry for Julie Aigner-Clark, the entrepreneur who created the best-selling line of “Baby Einstein” videos for… Continue Reading
Cancer-drug maker Aveo raises $53M
Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors.
New investors included Biogen Idec, Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group and Vatera Holdings, an investment vehicle… Continue Reading
Roundup: No-nukes cancer treatment, E. coli vaccines, ovarian-tissue banking, more
No nukes in lymphoma treatment – Two innovative biotech drugs that target tumor cells for destruction by tiny radioactive particles are struggling in the marketplace, in part because cancer doctors are simply too specialized to make proper use of them. The drugs — Zevalin (pictured at… Continue Reading
AstraZeneca ups the biotech ante
Now that AstraZeneca has made the bold — or impulsive — decision to snap up MedImmune for $15.6 billion in cash, one big question is whether the U.K. pharmaceutical giant has kicked Big Pharma’s appetite for biotech acquisitions into high gear.
The green-eyeshade types are generally… Continue Reading